title: Complete haematological and cytogenetic response to interferon alpha-2a of a myeloproliferative disorder with eosinophilia associated with a unique t(4;7) aberration.
abstract: A female patient with eosinophilia and cardiac symptoms was found to have a unique chromosomal aberration [t(4;7)(q11;p13)] of bone-marrow precursors. The disorder was classified as a chronic myeloproliferative syndrome with eosinophilia. Due to a significant increase in the white blood cell and eosinophil count during initial treatment with prednisone and hydroxyurea, Interferon alpha-2a was administered at a dose of 3-5 x 10(6) I.U. s.c., five times per week, and induced a long-term complete haematological and cytogenetic response. The clinical features of this case are presented and discussed in the context of the current literature.
authors.affiliation: Department of Haematology/Oncology, Hannover Medical School, Germany. Schoeffski.Patrick@MH-Hannover.de
authors.forename: P
authors.initials: P
authors.lastname: Schöffski
authors.forename: A
authors.initials: A
authors.lastname: Ganser
authors.forename: U
authors.initials: U
authors.lastname: Pascheberg
authors.forename: G
authors.initials: G
authors.lastname: Büsche
authors.forename: B
authors.initials: B
authors.lastname: Gaede
authors.forename: B
authors.initials: B
authors.lastname: Hertenstein
mesh_terms: D001854:Bone Marrow Cells / Q000473:pathology; D002894:Chromosomes, Human, Pair 4; D002897:Chromosomes, Human, Pair 7; D004802:Eosinophilia / Q000150:complications*; D005260:Female; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000235:genetics*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000235:genetics* / Q000627:therapeutic use*; D007621:Karyotyping; D009196:Myeloproliferative Disorders / Q000150:complications* / Q000188:drug therapy* / Q000235:genetics; D011994:Recombinant Proteins; D014178:Translocation, Genetic
chemical_list: D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins